Patent · US Active

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

US7982005B2 · kind B2 · utility

42Cited by

6References

11Claims

0Family size

Assignee

GlaxoSmithKline LLC · US

Inventors

Robert S. Ames · Havertown, US
Edward Appelbaum · Blue Bell, US
Irwin M. Chaiken · Gladwyne, US
Richard M. Cook · Chester Springs, US
Mitchell Stuart Gross · Wayne, US
Stephen Dudley Holmes · Epsom, GB
Lynette Jane McMillan · Ardmore, US
Timothy Wayne Theisen · Phoenixville, US

Key dates

Filing date	Mar 1, 2010
Grant date	Jul 19, 2011
Priority date	—
Expiry date	Mar 1, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.